As follow-up time extends, if the final overall survival is prolonged by osimertinib plus chemotherapy, the FLAURA2 strategy will be considered a superior standard first-line therapy for EGFR-mutated advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.